NCT07137390 2026-03-11A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal CancerM.D. Anderson Cancer CenterPhase 1/2 Withdrawn
NCT06047379 2026-03-02Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNeonc Technologies, Inc.Phase 1/2 Recruiting134 enrolled
NCT03828799 2026-02-27FOLFIRINOX-RInstitut du Cancer de Montpellier - Val d'AurellePhase 1/2 Completed13 enrolled 22 charts
NCT07071961 2026-02-17Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]M.D. Anderson Cancer CenterPhase 2 Suspended16 enrolled